GNFT — Genfit S.A.

Summary of GNFT Q4 2021 Earnings Call

1. Key Financial Results and Metrics:

• Revenue: €85.6 million in 2021, a significant increase from €7.8 million in 2020.
• Operating Expenses: Reduced to €53.8 million from €90.7 million in 2020.
• Operating Income: €31.8 million in 2021 compared to an operating loss of €82.9 million in 2020.
• Net Profit: €67.3 million in 2021, a turnaround from a net loss of €101.2 million in 2020.
• Financial Debt: Decreased from €185.7 million to €74.2 million.
• Cash Position: €258.8 million in cash and cash equivalents at year-end, up from €171 million in 2020.

2. Strategic Updates and Business Highlights:

• Ipsen Partnership: A landmark deal involving a €120 million upfront payment, with potential milestone payments up to €360 million and royalties up to 20% on future sales.
• Cost Control Measures: Implemented a restructuring plan that included significant headcount reductions and expense cuts, leading to a nearly 50% decrease in operational expenses.
• Clinical Development: Transitioning focus from NASH to PBC (Primary Biliary Cholangitis) with the ELATIVE study progressing towards top-line data expected in Q2 2023.
• NIS4 Diagnostic Technology: Recognized as a leading diagnostic tool for identifying at-risk NASH patients, although commercial opportunities are limited until a drug is approved for NASH.

3. Forward Guidance and Outlook:

• Operational Cash Burn: Expected to increase to €65 million in 2022, excluding potential business development expenses.
• Pipeline Development: Plans to advance two lead programs in ACLF (Acute on Chronic Liver Failure) and cholestatic diseases, with ongoing Phase 1 studies for NTZ and a new investigational compound for cholangiocarcinoma.
• Business Development: Open to acquiring both early-stage and clinical-stage assets to diversify the pipeline.

4. Bad News, Challenges, or Points of Concern:

• NASH Market Limitations: The current lack of approved therapies for NASH limits the market potential for NIS4 diagnostics.
• COVID-19 Impact: Recruitment for clinical trials was affected by the pandemic, particularly the Omicron variant, although recovery was noted in early 2022.
• Regulatory Engagement: Future timelines for proof-of-concept studies depend on regulatory discussions, introducing uncertainty.

5. Notable Q&A Insights:

• Business Development Strategy: Management expressed interest in both early and clinical-stage assets, particularly for complex diseases like ACLF, emphasizing the need for multiple mechanisms of action.
• NTZ Mechanism of Action: Highlighted NTZ's dual role as an antibiotic and anti-inflammatory agent, with promising preclinical data supporting its potential in ACLF.
• Market Positioning for NIS4: While technical development is strong, commercial success is contingent on the approval of NASH therapies, which remains a significant hurdle.

Overall, GNFT demonstrated a strong financial turnaround in 2021, pivoting strategically towards new therapeutic areas while managing operational costs effectively. However, challenges remain, particularly in the NASH market and the impact of the pandemic on clinical trials.